The primary cause is a drop in oestrogen. Oestrogen keeps vaginal tissues thick, moist, and elastic. When levels fall, the tissues thin, the glands that produce lubrication become less active, and the vaginal pH shifts, making the area more prone to irritation and infection.
Oestrogen levels drop in several situations. Menopause is the most common, whether natural, surgical (following removal of the ovaries), or induced by medical treatment. Breastfeeding causes a temporary but significant drop in oestrogen that can produce the same symptoms. Cancer treatments including chemotherapy, radiation to the pelvis, and hormonal therapies used for breast or gynaecological cancers frequently cause vaginal atrophy as a side effect. Some medications reduce oestrogen levels as part of their mechanism, including certain treatments for endometriosis and uterine fibroids.
Other contributing factors include smoking, which reduces blood flow to vaginal tissue and lowers oestrogen levels, insufficient sexual activity, which reduces natural lubrication over time, and the use of fragranced soaps, douches, or synthetic sanitary products that disrupt the vaginal environment.
Without treatment, vaginal dryness and atrophy worsen progressively. The tissue continues to thin and loses elasticity, making the condition harder to reverse the longer it is left.
Pain during intercourse becomes severe enough that many women avoid sexual activity entirely, which affects relationships and mental health. Recurrent urinary tract infections develop because the thinned, dry tissue provides less protection against bacteria. Urinary symptoms including urgency, frequency, and burning during urination worsen as the urethra is affected by the same tissue changes. In advanced atrophy the vaginal opening can narrow, making even a gynaecological examination painful.
Unlike hot flashes and night sweats, which often improve on their own after menopause, vaginal dryness and atrophy do not resolve without treatment. They get worse year on year if left unmanaged.
Vaginal dryness and atrophy present differently depending on the underlying cause and how far the tissue changes have progressed.
Menopause-related atrophy is the most common form and involves progressive thinning and drying of the vaginal and vulval tissues as oestrogen declines naturally after the final menstrual period. Treatment-induced atrophy occurs as a side effect of cancer treatments or hormonal therapies and can develop rapidly, sometimes within weeks of starting treatment. Lactational atrophy is a temporary form that occurs during breastfeeding and typically resolves once breastfeeding stops and hormones normalise. Premature atrophy affects women who experience early menopause before the age of 40, whether spontaneously or surgically induced.
Treatment depends on the underlying cause, the severity of symptoms, the patient's hormonal status, and whether there are any contraindications to oestrogen-based therapy.
Vaginal dryness related to menopause cannot be entirely prevented, but the following steps reduce severity and slow progression.
Use fragrance-free, pH-balanced washing products for the genital area and avoid douching, which strips the natural protective environment of the vagina. Wear loose, breathable cotton underwear and avoid synthetic fabrics that trap heat and moisture. Stay hydrated and maintain a balanced diet that supports general hormonal health. Avoid smoking, as it worsens tissue blood flow and lowers oestrogen levels. Regular sexual activity, including solo activity, maintains blood flow and lubrication in the vaginal tissue. Start vaginal moisturisers early, around the time of perimenopause, rather than waiting for symptoms to become severe. Discuss prophylactic topical oestrogen with a gynaecologist at the start of menopause rather than after symptoms have progressed.
Diagnosis is primarily clinical and is made through a detailed consultation covering symptoms, menstrual history, obstetric history, current medications, and any relevant medical history such as cancer treatment.
A pelvic examination assesses the appearance of the vaginal and vulval tissue, looking for characteristic signs of atrophy including pallor, reduced rugae (the natural folds of the vaginal wall), tissue fragility, and narrowing of the vaginal opening. A vaginal pH test is a simple, painless test where a pH strip placed at the vaginal wall confirms whether the pH has shifted to the alkaline range that is characteristic of atrophy. Vaginal cytology, where a swab of vaginal cells is examined under microscopy, can confirm the degree of tissue change. Hormone blood tests including FSH, LH, and oestradiol levels confirm menopausal status and help guide treatment decisions. A vaginal swab is taken where infection is suspected alongside atrophy, since recurrent infections are common in this condition.
At the initial consultation, bring a list of all medications including any supplements and over-the-counter products, as some interact with hormonal treatments or contribute to vaginal dryness directly. Inform your doctor of any personal or family history of hormone-sensitive cancers, blood clots, or cardiovascular disease, as this affects which treatment options are suitable.
Stop using fragranced soaps, intimate washes, and synthetic sanitary products before attending, as these alter the vaginal environment and can affect examination findings. If you have been using any vaginal products including moisturisers or creams, mention these at the consultation and note how long you have been using them.
If systemic HRT or laser treatment is being considered, a general health review including blood pressure, weight, and breast examination is conducted before treatment is started.
The timeline for improvement varies by treatment. Vaginal moisturisers provide relief within days of starting use. Topical vaginal oestrogen typically produces noticeable improvement in dryness and discomfort within 4 to 6 weeks, with full tissue restoration taking 3 to 6 months of consistent use. Systemic HRT produces broader symptom relief within 4 to 12 weeks. Laser and radiofrequency treatments produce gradual improvement over 6 to 12 weeks after each session, with most patients needing two to three sessions for optimal results.
Continue using prescribed or recommended treatment as directed. Do not stop vaginal oestrogen because symptoms have improved — the improvement is maintained by the treatment, not despite it. Stopping causes symptoms to return, usually within weeks.
Use fragrance-free emollient on the vulval area to maintain skin hydration alongside vaginal treatment. Continue avoiding irritating products. Return for follow-up at the interval advised by your specialist, typically at 3 months initially and then annually once symptoms are stable.
Most treatments for vaginal dryness involve no downtime. Topical oestrogen, moisturisers, lubricants, and oral medications can be started and continued without any period of restricted activity.
After laser or radiofrequency treatment, avoid sexual intercourse, swimming, and use of tampons for 5 to 7 days after each session to allow the treated tissue to heal. Some warmth or mild discomfort in the vaginal area for 24 to 48 hours after laser treatment is normal. Cool compresses provide relief. Avoid hot baths, saunas, and strenuous exercise for 48 hours after the procedure.
Most women who start topical oestrogen or HRT notice improvement in vaginal dryness within 4 to 6 weeks and a return to comfortable sexual activity within 3 months. For women who have had severe or longstanding atrophy, recovery takes longer and patience with the treatment timeline is important. If there is no improvement after 3 months of topical oestrogen, discuss alternative treatments or a higher-dose formulation with your specialist.
It is common but not something that has to be accepted as unavoidable. Effective treatments are available for most women and the condition responds well to treatment when addressed early.
Many breast cancer survivors can use low-dose topical vaginal oestrogen safely, as blood levels remain minimal when applied locally. This is a decision made individually between the patient and their oncologist and gynaecologist, taking into account the type of cancer, the treatment received, and the current risk profile. It should not be assumed to be either automatically safe or automatically contraindicated without specialist review.
Vaginal atrophy is a chronic condition related to the ongoing hormonal state after menopause. Most women need to continue treatment for as long as they want to maintain the benefit. There is no fixed end point. Annual review ensures the treatment remains appropriate.
Over-the-counter creams are not effective for lichen sclerosus. The condition requires prescription-strength corticosteroids prescribed and monitored by a specialist. Using the wrong product delays treatment and can worsen symptoms.
Yes. Vaginal moisturisers, lubricants, hyaluronic acid therapy, laser vaginal rejuvenation, radiofrequency therapy, and ospemifene are all non-oestrogen options. A gynaecologist can help identify which is the most appropriate based on your symptoms and medical history.
Yes. Restoring vaginal tissue health directly reduces pain during intercourse and improves lubrication. Most women report meaningful improvement in sexual comfort within 3 months of starting treatment. Using a vaginal lubricant at the time of intercourse alongside a longer-term treatment accelerates this.
Yes. Women who are breastfeeding, undergoing cancer treatment, taking certain hormonal medications, or who experience premature menopause can develop vaginal dryness and atrophy at any age. The treatment approach is the same but is tailored to the specific cause.
